Previous 10 | Next 10 |
Encinitas, California--(Newsfile Corp. - March 8, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced the publication of results from a Phase 1 double-masked study of KIO-101, a potent, non-steroidal anti-inflammatory agent. KIO-101 contains the same active ...
A look at the top 10 most actives in the United States PROSHARES TRUST (SQQQ) fell 3.4% to $12.34 on volume of 161,376,033 shares New York Community Bancorp Inc. (NYCB) fell 11.1% to $5.75 on volume of 125,980,698 shares Plug Power Inc. (PLUG) rose 5.6% to $4.7 on volume of 111,112,179 sh...
A look at the top 10 most actives in the United States PROSHARES TRUST (SQQQ) fell 3.3% to $12.36 on volume of 132,876,575 shares New York Community Bancorp Inc. (NYCB) fell 8.1% to $5.945 on volume of 103,690,183 shares Plug Power Inc. (PLUG) rose 2.4% to $4.555 on volume of 100,620,245 ...
2024-01-31 19:03:10 ET More on Kiora Pharmaceuticals Seeking Alpha’s Quant Rating on Kiora Pharmaceuticals Historical earnings data for Kiora Pharmaceuticals Financial information for Kiora Pharmaceuticals Read the full article on Seeking Alpha ...
$15 million in upfront financing with the potential to receive up to an additional approximately $30 million in potential warrant exercise proceeds for an aggregate of up to approximately $45 million in total gross proceeds Encinitas, California--(Newsfile Corp. - January 31, 2024) - Kiora Pharm...
Kiora to webcast investor conference call at 5:30 pm today; details below Encinitas, California and Clermont-Ferrand, France--(Newsfile Corp. - January 31, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), a clinical-stage biotech company developing treatments for orphan retinal disease...
--News Direct-- Kiora Pharmaceuticals CEO Brian Strem joined Steve Darling from Proactive to share news the company's plan to broaden the clinical development of KIO-301, a treatment designed for various inherited retinal diseases. The expansion includes initiating a Phase 2 trial whi...
Encinitas, California--(Newsfile Corp. - November 9, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced its third quarter 2023 financial results and is providing an update on its plans to advance clinical development of KIO-301 for other inherited reti...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Kiora Pharmaceuticals Inc. (KPRX) is expected to report $-0.3 for Q3 2023
News, Short Squeeze, Breakout and More Instantly...
Kiora Pharmaceuticals Inc. Company Name:
KPRX Stock Symbol:
NASDAQ Market:
Encinitas, California--(Newsfile Corp. - June 25, 2024) - Kiora Pharmaceuticals (NASDAQ: KPRX) has appointed Roger A. Goldberg, MD, MBA, a vitreoretinal surgeon at Bay Area Retina Associates (BARA) to its Scientific Advisory Board. As an advisor, Dr. Goldberg will contribute scientific insights a...
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available...
Encinitas, California--(Newsfile Corp. - May 20, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), will participate in two upcoming investor conferences that will be available to investors live with the replay available on-demand. On Wednesday May 22, at 3:00...